HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

High-Dose Statins Could Go OTC In UK

Executive Summary

The NHS wants to make high dose statins available OTC in the UK and will work with regulators and industry to make it happen. Such a switch could open up a whole new consumer health category in the country, moving the industry into treatments for chronic conditions. 

You may also be interested in...



Prescription-To-OTC Switch Of Daily Contraceptives And High-Dose Statins In The UK?

Daily contraceptives and high-dose statins are two OTC categories that have future switch potential, according to UK self-care industry association CEO John Smith. 

Menarini Grows In Spain With Five Launches

Italy's Menarini is expanding its portfolio in Spain with the launches of three new supplements and a couple of oral care products.

Daring To Be 'Different' Lands Infirst In Hot Water

ASA tells Infirst that use of the word "different" in marketing implies its Flarin analgesic is more effective than other ibuprofen OTC drugs sold in the UK.

Topics

Related Companies

UsernamePublicRestriction

Register

RS149187

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel